|Bid||83.09 x 1200|
|Ask||83.12 x 1300|
|Day's Range||81.91 - 83.87|
|52 Week Range||75.52 - 110.37|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||38.07|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With its stock down 5.3% over the past three months, it is easy to disregard Incyte (NASDAQ:INCY). However, stock...
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
Last month, we presented updated data for RUX cream at the American Academy of Dermatology meeting, including the two-year data from our Phase 2 vitiligo trial and updated pooled results from our Phase 3 TRuE-AD program in atopic dermatitis with each highlighting the exciting potential of ruxolitinib cream as a treatment for these two indications. If approved baracitinib could be the first FDA approved therapy in alopecia areata.